



06-0501

1642#
✓Express Mail No.: EL 501 640 114 USIN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

In re Application of: Francisco et al.

Serial No.: 09/724,406

Filed: November 28, 2000

For: RECOMBINANT ANTI-CD30
ANTIBODIES AND USES THEREOF

Examiner: Davis, N.

Group Art Unit: 1642

Attorney Docket No.: 9632-006-999

JUN 08 2001

TECH CENTER 1600/2900

#8
B.G.J.
6/14/01**PROVISIONAL ELECTION UNDER 37 C.F.R. § 1.143**Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the outstanding Office Action dated April 2, 2001, in which the Examiner imposed a restriction requirement, please consider the following remarks. Submitted concurrently herewith is an Information Disclosure Statement, a List of References Cited by Applicants, and copies of references AA-BK. Also submitted concurrently herewith is a Petition for Extension of Time.

REMARKS

The Examiner has required an election under 35 U.S.C. § 121 of one of the following inventions:

- | | |
|------------|--|
| Group I. | Claims 1-19, drawn to a method of treatment or prevention of Hodgkin's disease, classified in class 424, subclass 193.1; |
| Group II. | Claims 20-33, drawn to a pharmaceutical composition, classified in class 387.1, subclass 387.1; and |
| Group III. | Claims 34-52, drawn to an isolated nucleic acid, classified in class 536, subclass 23.1. |

The Examiner contends that each of the above groups of claims are distinct.

In response, Applicants hereby provisionally elect to prosecute the claims of Group I, namely claims 1-19, drawn to a method of treatment or prevention of Hodgkin's disease, with traverse.